Biotech Catches Eye Of Bill Gates by Ron Winslow. The Wall Street Journal. January 18, 2013.
Foundation Medicine Inc. makes a $5,800 test that analyzes biopsies for some 280 genetic mutations that are suspected of driving tumor growth. Several big drug companies are using the test to identify new drug targets. Mr. Gates was drawn to invest in the company after discussions with Michael Pellini, the CEO as well as background conversations with Eric Lander of the Broad Institute, and Silicon Valley venture capitalists.
No comments:
Post a Comment